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Background: The tumor microenvironment (TME) of human glioblastoma (GBM) exhibits
considerable immune cell infiltration, and such cell types have been shown to be
widely involved in the development of GBM. Here, weighted correlation network analysis
(WGCNA) was performed on publicly available datasets to identify immune-related
molecules that may contribute to the progression of GBM and thus be exploited as
potential therapeutic targets.
Methods: WGCNA was used to identify highly correlated gene clusters in Chinese
Glioma Genome Atlas glioma dataset. Immune-related genes in significant modules were
subsequently validated in the Cancer Genome Atlas (TCGA) and Rembrandt databases,
and impact on GBM development was examined in migration and vascular mimicry
assays in vitro and in an orthotopic xenograft model (GL261 luciferase-GFP cells) in mice.
Results: WGCNA yielded 14 significant modules, one of which (black) contained genes
involved in immune response and extracellular matrix formation. The intersection of these
genes with a GO immune-related gene set yielded 47 immune-related genes, five of
which exhibited increased expression and association with worse prognosis in GBM.
One of these genes, TREM1, was highly expressed in areas of pseudopalisading cells
around necrosis and associated with other proteins induced in angiogenesis/hypoxia. In
macrophages induced from THP1 cells, TREM1 expression levels were increased under
hypoxic conditions and associated with markers of macrophage M2 polarization. TREM1
siRNA knockdown in induced macrophages reduced their ability to promote migration
and vascular mimicry in GBM cells in vitro, and treatment of mice with LP-17 peptide,
which blocks TREM1, inhibited growth of GL261 orthotopic xenografts. Finally, blocking
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the cytokine receptor for CSF1 in induced macrophages also impeded their potential to
promote tumor migration and vascular mimicry in GBM cells.
Conclusions: Our results demonstrated that TREM1 could be used as a novel
immunotherapy target for glioma patients.
Keywords: glioblastoma, macrophages, tumor microenvironment, M2 polarization, bioinformatics, TCGA
INTRODUCTION
Glioblastoma (GBM) is one of themost deadly types of malignant
solid tumor. Despite considerable effort toward the molecular
understanding and treatment of the disease, the patient survival
rate remains dismally low. The 5-year survival rate of 6.8%
is especially low for GBM relative to all tumor types (1).
A compounding problem for the incidence of GBM is the
increasing longevity of the human population worldwide. In the
United States, the incidence of GBM is estimated to be 3.22 per
100,000 individuals (1). However, the incidence of glioma rises
rapidly with increasing age, reaching a peak incidence of 15.29
per 100,000 individuals in the elderly between the ages of 75
and 84 (1). Therefore, the development of effective treatment
strategies to prevent the progression of GBM and improve the
quality of life for patients is urgently needed.
In recent years, a molecular classification scheme adopted by
the World Health Organization (WHO) has provided insight
into the response of GBMs to current treatment strategies (2, 3).
GBMs are now categorized as one of four molecular subtypes
with variants in isocitrate dehydrogenase genes (IDH) generally
appearing in cases that exhibit better overall survival. Although
genetic changes reveal the precise molecular pathways corrupted
during the development of individual GBMs, the biology of the
brain poses additional challenges for treatment; it is a critical
organ with an extremely rich blood supply, a complete blood-
brain barrier (BBB), and a parenchyma lacking immune cells.
Such features constitute the tumor microenvironment (TME)
of GBM, which is increasingly becoming a therapeutic target
of interest, in part due to the role immune cells play in
tumor development.
In the last decade, checkpoint blockade immunotherapy has
shown remarkable success in treating a variety of tumors,
including advanced melanoma (4), non-small-cell lung cancer
(NSCLC) (5), and Hodgkin’s lymphoma (6). A series of clinical
trials investigating the efficacy of checkpoint inhibitors in GBM
showed that only a small subset of patients (8%) demonstrated
objective responses (7). One possible explanation for this result
is the lower tumor mutational burden of GBM (8) and the
low level of T-cell infiltration (9). However, a more rigorous
understanding of the biology of other immune cell types, such
as tumor-associated macrophages (TAMs), which promote or
inhibit the progression of GBM through the secretion of multiple
cytokines (10, 11), might also provide new therapeutic targets
of interest.
In this study, we performed weighted correlation network
analysis (WGCNA), which identifies/generates highly correlated
gene clusters by summarizing such clusters using module
clustering or the identification of intramodular hub genes (12),
to specifically identify immune-related genes associated with the
development and/or prognosis of GBM from publicly available
datasets, namely The Cancer Genome Atlas (TCGA), the Chinese
Glioma Genome Atlas (CGGA), and Rembrandt. The analysis
yielded a gene called TREM1. Inhibition of TREM1 reduced
migration and vascular mimicry in vitro, and tumor growth in
vivo, possibly through decreased release of the cytokine CSF1.
Thus, targeting TREM1 might be of therapeutic value in the
treatment of human GBM.
MATERIALS AND METHODS
Microarray Data
Microarray data for human gliomas were downloaded from The
Cancer Genome Atlas (TCGA, http://cancergenome.nih.gov/
abouttcga) (13), the Chinese Glioma Genome Atlas (CGGA,
http://www.cgga.org.cn/) (14), and the Rembrandt brain cancer
dataset (http://www.betastasis.com/glioma/rembrandt/) (15).
These datasets include whole-genome expression profiles and
corresponding clinical information of the patients.
The CGGA expression dataset was collected using the Agilent
Whole Human Genome Microarray platform and includes data
from a total of 301 glioma samples. All probe sets were mapped
to gene symbols according to the probe annotation files of
the GPL4133 platform, and gene expression values were log2
transformed. The TCGA and Rembrandt databases have been
previously described.
Weighted Gene Co-expression Networks
and Their Modules
WGCNA is a freely accessible R software package (version R
3.4.3) developed for the construction of weighted gene co-
expression networks. Rather than focusing only on differential
gene expression, WGCNA uses information from the genome to
identify a set of genes of interest and converts the associations
of thousands of genes with phenotypes into associations between
several gene sets and phenotypes, eliminating the problem
of multiple hypothesis test correction. The parameter β is
a soft-thresholding power parameter that strengthens strong
correlations and penalizes weak correlations between genes.
A hierarchical clustering tree was constructed, with different
branches of the tree representing different gene modules. The
adjacency matrix was transformed into a topological overlap
matrix (TOM). Genes were divided into different gene modules
based on the TOM-based dissimilarity measure.
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Module Genetic Analysis and Sub-network
Analysis
Gene ontology (GO) (16) and Kyoto Encyclopedia of Genes
and Genomes (KEGG) (17) analyses were used to explore the
biological function of the module with the highest correlation
with clinical traits and to screen hub genes. The STRINGdatabase
(https://string-db.org/) (18) is currently the largest database of
protein interactions. All genes in the selected module were
first analyzed by GO and KEGG pathway enrichment analysis
using DAVIDweb tools (https://david.ncifcrf.gov/home.jsp) (19).
A plug-in for Cytoscape (20), MCODE (21), determines the
hub gene and extracts sub-networks based on the degree of
connectivity of genes to surrounding genes in the network. Hub
genes were defined as those with gene significance (GS)> 0.3 and
module membership (MM) > 0.8.
Cell Culture and Induction of THP-1 Cell
Differentiation
Human GBM cell lines U87MG and LN229 and the mouse GBM
cell line GL261 were purchased from the Chinese Academy of
Sciences Cell Bank (Shanghai, China). The human monocyte
leukemia cell line (THP-1) was a kind gift from Professor Yuan
Guo, Department of General Medicine, Shandong University.
U87MG, LN229, GL261, and THP1 were cultured in Dulbecco’s
modified Eagle’s medium (DMEM; Thermo Fisher Scientific;
Waltham, MA, USA) supplemented with 10% fetal bovine serum
(FBS; Thermo Fisher Scientific). THP-1 cells were treated with
200 nM phorbol-12-myristate-13-acetate (PMA; Sigma-Aldrich;
St. Louis, MO, USA) for 24 h to allow for differentiation into
macrophages in six-well plates. All cells were maintained at 37◦C
in a cell incubator containing 5% CO2.
Gene Silencing
RNA interference (RNAi) technology was used to knock
down the expression of target genes. Small interfering RNAs
(siRNA) were synthesized (GenePharma; Shanghai, China) and
transfected into cells using Lipofectamine 2000 (Thermo Fisher
Scientific) according to the manufacturer’s protocol. Knockdown
efficiency was evaluated 48 h after transfection using RT-qPCR
and Western blotting. Sequences of the siRNA (n = 2) that




Real-Time Quantitative PCR (RT-qPCR)
Total RNA was isolated from GBM cells using the RNA-Quick
Purification Kit (Shanghai YiShan Biotechnology; Shanghai,
China) according to the manufacturer’s protocol. Reverse
transcription was conducted using the ReverTra Ace qPCR RT
Master Mix Kit (FSQ-101, TOYOBO; Osaka, Japan), and cDNA
was used as the template in real-time fluorescence quantification.
RT-qPCR was performed with the hot start reaction mix SYBR
Green Master (Roche; Basel, Switzerland) on a Real-Time PCR
Detection System (Roche 480II). Independent experiments were
conducted in triplicate, and ACTB served as an internal control.
The following primers were used:
TREM-1: F 5′-TTTGTTTCCCAGTCTGTGTGC-3′, R
5′-TCCCCTATTCTCCATCACCACT-3′; ACTB: F 5′-CATG
TACGTTGCTATCCAGGC-3′, R 5′- CTCCTTAATGTCACGC
ACGAT-3′; CD206: F 5′-CGAAATGGGTTCCTCTCTGGT-3′,
R 5′-TTTATCCACAGCCACGTCCC-3′; CD163: F 5′-GTAG
TCTGCTCAAGATACACAGAA-3′, R 5′-GCGTTTTGAGCT
CCACTCTG-3′; IL1B: F 5′-TGATGGCTTATTACAGTGGA-3′,
R 5′-GGTCGGAGATTCGTAGCTGG-3′; CSF1: F 5′-CTCC
AGCCAAGATGTGGTGA-3′, R 5′-TCAGAGTCCTCCCAGG
TCAA-3′; CSF2: F 5′-AGCCCTGGGAGCATGTGAAT-3′,
R 5′-GCAGCAGTGTCTCTACTCAGG-3′; IL6 F 5′-CCTG
AACCTTCCAAAGATGGC-3′, R 5′-TTCACCAGGCAA
GTCTCCTCA-3′; CXCL: F 5′-TGTGAAGGTGCAGTTT
TGCC-3′, R 5′-GGGGTGGAAAGGTTTGGAGT-3′; TGF-α: F
5′-GTTGTAGCAAACCCTCAAGCTG-3′, R 5′-GAGGTACA
GGCCTCTGATG-3′; VEGFA: F 5′-AAAACACAGACTCGCG
TTGC-3′, R 5′-CCTCGGCTTGTCACATCTGC-3′.
Western Blotting
Treated cell samples were lysed 30min in RIPA buffer
(Thermo Fisher Scientific) supplemented with the protease
inhibitor phenylmethanesulfonyl fluoride (PMSF, Beyotime
Biotechnology, Shanghai, China). Protein lysates were
separated with 10% sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) and electrophoretically
transferred to polyvinylidene difluoride (PVDF) membranes
(0.22µm, Merck Millipore; Darmstadt, Germany). Membranes
were blocked at room temperature for 1 h in Tris-buffered saline
with Tween-20 (TBST;10mM Tris, 150mM NaCl, and 0.1%
Tween 20) containing 5% skim milk powder (Beyotime) and
incubated overnight with primary antibody at 4◦C, followed the
next day by incubation with a secondary antibody conjugated
to horseradish peroxidase (HRP) reconstituted in antibody
dilution buffer (dilution 1: 5000; Beyotime) for 1 h at room
temperature. Specific proteins were visualized with enhanced
chemiluminescence (ECL, Millipore; Bedford, MA, USA)
according to the manufacturer’s protocol. The following primary
antibodies were used: rabbit anti-TREM1 (PA5-95477, Thermo
Fisher Scientific); rabbit anti-ACTB (20536-1-AP, Proteintech
Group, Inc.; Wuhan, China).
Cell Migration Assay
Transwell assays were performed in Transwell chambers (8µm;
Corning Costar; Corning, NY, USA). Cells were cultured
in complete medium and supernatant with corresponding
treatments (volume ratio: 1:1) for 72 h. Cells (2× 104) in DMEM
medium (200 µL) were then seeded in the top chamber. The
lower chamber was filled with medium (600 µL) containing 30%
FBS. The chambers were incubated for 24 h. Cells that migrated
to the lower surface were fixed with 4% paraformaldehyde
(Solarbio; Beijing, China), stained with crystal violet (Solarbio)
for 15min, and counted under bright field microscopy (Leica
DMi8; Leica Microsystems, Wetzlar, Germany). Images were
acquired from 5 random fields in each well.
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Vasculogenic Mimicry (VM) Formation
Assay
The VM formation assay was performed as described previously.
Briefly, 96-well tissue culture plates were coated with Matrigel
(0.1 mL/well; Corning; Bedford, MA, USA) and allowed to
polymerize for 0.5 h at 37◦C. Cells were cultured in complete
medium and supernatant with corresponding treatments
(volume ratio:1:1) for 72 h. Cells were resuspended, and 100 µL
of suspension was seeded onto Matrigel at 2 × 105 cells/mL and
subsequently incubated without serum in 5% CO2 at 37
◦C for
6 h. Cultures were photographed using a Leica microscope (Leica
DMi8; Leica Microsystems, Wetzlar, Germany).
Orthotopic Xenograft Model
GL261 cells infected with lentivirus expressing luciferase-GFP
cells (3 × 105; OBiO Technology; Shanghai, China) were
stereotactically implanted into the brains of 6-week-old C57BL/6
mice. After 7 days, tumor size was determined, and animals
were divided into the following two groups: Control group,
n = 6, and LP-17 group, n = 6. Mice were administered
50 µg of diluted control peptide (TDSRCVIGLYHPPLQVY)
or 50 µg of LP-17 (LQVTDSGLYRCVIYHPP), respectively, by
intravenous injection every day (GL Biochem; Shanghai, China).
Tumor volume was monitored using bioluminescence imaging
(PerkinElmer IVIS Spectrum; Waltham, MA, USA). At the end
of the experiment, tumors were dissected and frozen in liquid
nitrogen or fixed in formalin for further analysis.
Immunohistochemistry (IHC)
Tumors were removed from sacrificed mice, fixed in 4%
paraformaldehyde and embedded in paraffin. Paraffin-embedded
samples were sectioned (4µm) and fixed on glass slides.
Epitope retrieval of sections was performed in 10 mmol/L
citric acid buffer at pH7.2 heated in a microwave. Slides were
subsequently incubated with the primary antibody (rabbit anti-
CD11b, dilution 1:200, ab133357, Abcam; Cambridge, UK) at
4◦C overnight followed by HRP-conjugated secondary antibody
for 1 h at room temperature. Antibodies were detected using the
substrate diaminobenzidine (DAB, Beyotime), and slides were
counterstained with hematoxylin (Beyotime). Staining degree
(scores of 0: negative, 1: light yellow, 2: light brown, and 3:
dark brown) and positive ratio (scores of 1: 0–25%, 2: 26–50%,
3: 51–75%, and 4: 76–100%) were used as scoring methods for
statistical analysis.
Periodic Acid-Schiff (PAS) Stain
Briefly, slides were deparaffinized, hydrated in distilled water,
immersed in PAS solution for 5min, rinsed 4 times, incubated in
Schiff ’s Solution for 15min and counterstained with hematoxylin
for 2–3 min (Solarbio).
Immunofluorescence Staining
Tissue slices or VM cells were fixed with 4% paraformaldehyde
at 4◦C for 15min and incubated in 0.3% Triton X-100 for
15min. After blocking with 5% goat serum for 30min,
tissue slices or VM cells were incubated with corresponding
primary antibodies against TREM1 (1:200), CD11b (1:200),
CD68 (1:200), and VEGFR2 (1:200) at 4◦C overnight and
then incubated with Alexa Fluor 488-conjugated or Alexa
Fluor 594-conjugated secondary antibodies (Beyotime) for
2 h. DAPI (Beyotime) was used to stain the nuclei. The
immunofluorescent signals were detected by fluorescence
microscopy (Leica DMi8; Leica Microsystems, Wetzlar,
Germany). The following primary antibodies were used:
rabbit anti-CD68 (ab213363, Abcam; Cambridge, UK);
rabbit anti-VEGFR2 (26415-1-AP, Proteintech Group, Inc.;
Wuhan, China).
Plotting and Statistical Analysis
Each assay was performed at least three times independently.
Data analysis was performed using GraphPad Prism 8
software (San Diego, CA, USA). Data were reported as the
mean ± SD. The statistical significance of experimental
data was evaluated using the Student’s t-test between two
groups and one-way analysis of variance (ANOVA) among
more groups. A Chi-square test was used to determine the
association between TREM1 expression and pathological
characteristics. The Pearson correlation was applied to
evaluate the linear relationship between gene expression
levels. In addition, for microarray data in a common
database, non-parametric tests were used to detect differences.
A log-rank model was used for single-variate survival
analysis, whereas a COX regression model was used for
multivariate survival analysis. Differences were considered to
be significant at the following p-values: ∗P < 0.05; ∗∗P < 0.01;
∗∗∗P < 0.001.
RESULTS
WGCNA Identifies Key Modules in Glioma
Expression Data
To find the key modules associated with GBM clinical traits,
we performed WGCNA on the CGGA glioma dataset. Clinical
sample information includes gender, age, TCGA-subtype, WHO
grade, progression-free survival time (PFS), and overall survival
(OS). All samples were first clustered using the FlashClust
package, and “150” was chosen as the criterion to exclude atypical
samples (Figure 1A). The soft-thresholding power was set as
“5,” and a topological matrix with non-scale features (scale-
free R2 = 0.84) was obtained (Figures 1A,B). The clustering
dendrograms of the sample matched the strip chart for clinical
features (Figure 1B). The topological overlapping heat map
depicted the TOM including all genes (Figure 1C). The topology
matrix was clustered using the dissimilarity between genes and
then divided into different modules. We eventually identified
14 modules (Figure 1D; non-clustering genes shown in gray). A
module and sample trait correlation heatmap was created based
on correlations between module eigengenes and clinical traits
(Figure 1D). Finally, an eigengene adjacency heatmap showed
the correlation between different modules (Figure 1C). These
steps represent the general flow of analysis of expression datasets
using WGCNA. Black, green, magenta, tan, and pink modules
emerged as the most significant from the analysis.
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FIGURE 1 | WGCNA and identification of significant modules. (A) Sample dendrogram and clinical trait heatmap. The cutoff value of the sample dendrogram is set to
150 to exclude samples with high variability. The samples are clustered according to clinical features (gender, age, TCGA-subtype, WHO grade, PFS, and OS).
Gender: white represents male, gray represents female. Age, PFS, and OS: color depth is positively correlated with value. TCGA-subtype: blue represents neural
subtype, yellow represents proneural subtype, green represents classical, and white represents mesenchymal. White, pink, and red represent WHO grades II, III, and
IV, respectively. (B) Cluster dendrogram obtained from transcriptomic data of glioma in the CGGA database with average hierarchical linkage clustering. The color row
underneath the dendrogram shows the module assignment determined by Dynamic Tree Cut and Merged Dynamic. Comparison between Dynamic Tree Cut and
Merged Dynamic shows that the black and dark blue modules merge into a new black module, which means that the expression characteristics of the genes in the
black module are more different. (C) Network heatmap of the whole genome. In the heatmap, each row and column corresponds to a gene; light color denotes low
topological overlap, and progressively darker red denotes higher topological overlap. Darker squares along the diagonal correspond to modules. The gene
dendrogram and module assignment are shown along the left and top. (D) Module–trait relationship heatmap. Hierarchical clustering of module eigengenes that
summarize the modules found in the clustering analysis. The row represents the module, and the column represents the trait. The values in the box indicate the
correlation and p-value.
Analysis of Black Module Genes
From the module–trait correlations heatmap, we identified the
black module as highly correlated with clinical traits (correlation
coefficient = 0.64, P = 1.1E-175; Figure 2A). The black module,
containing a total of 1,518 genes (Figure 2A), was positively
correlated with the pathological grade of glioma and negatively
correlated with PFS, OS, and TCGA subtypes. To reveal the
potential biological functions of the genes within the black
module, we conducted GO and KEGG analyses. The GO
terms emerging as the most significant were biological process
(BP), cellular component (CC), and molecular function (MF)
(Figure 2B). GO analysis indicated that genes within the black
module weremainly involved in immune response, inflammatory
response, angiogenesis, cell surface receptor signaling, and
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FIGURE 2 | Genes in the black module are involved in immune responses and the formation of extracellular matrix. (A) Scatterplot of gene significance for survival
time (y-axis) vs. module membership (x-axis) in the black module. The correlation coefficient between them is 0.64 (p-value:1.1e-175). (B) Histogram of GO analysis
for all genes in the black module. MF, CC, and BF respectively represent molecular function, biological process, and cellular component. The FDR values of the
corresponding MF items are: 5.71E-07, 1.06E-36, 9.25E-36, 0.089116, 1.8E-18, 0.007131, 6.21E-32, 4.83E-07, 0.007879, 0.001471, 9.37E-11, 2.63E-11,
2.43E-10, 0.002713, and 0.000293; CC items: 1.25E-21, 3.71E-32, 1.72E-07, 8.90E-24, 4.61E-07, 4.83E-14, 6.92E-06, 5.71E-17, 3.35E-11, and 2.63E-06; BF
items: 5.64E-05, 7.84E-04, 7.04E-06, 1.82E-15, 1.51E-05, 30E-08, 1.75E-06, 6.34E-04, 0.001701, and 2.39E-09. (C) Bubble chart of KEGG pathway analysis for all
genes in the black module. (D) Protein–protein network constructed by all genes in the black module. Genes were divided into some subnets based on degree of
connection. The figure shows the two largest subnetworks. Most of the genes in these subnets are involved in immune responses and the formation of extracellular
matrix.
leukocyte migration. KEGG pathway analysis revealed that these
genes were involved in cytokine–cytokine interaction, ECM–
receptor interaction, PI3K-Akt signaling, cell adhesion, and
phagosomes (Figure 2C). All genes in the black module were
input into String to construct a protein–protein interaction
network (Supplementary Figure 2B) and then divided into
several sub-networks. By setting the module membership (MM)
to > 0.8 and the gene significance (GS) to > 0.3, we selected
15 hub genes from the black module: LAMC1, LANB1, CIITA,
SERPINE1, HLA-A, HLA-DBQ, IFI30, CD53, ITGB2, PTAFR,
FAM20A, FN1, CCR5, LCP2, and CGR2B. These core genes are
mainly involved in the immune response and the formation
of extracellular matrix. The two largest sub-networks are
also shown (Figure 2D). Genes from the sub-networks are
mainly involved in immune reactions, inflammatory reactions,
extracellular matrix, and cell adhesion. These results led us
to focus on the genes involved in the immune response in
subsequent analysis.
Frontiers in Immunology | www.frontiersin.org 6 July 2020 | Volume 11 | Article 1281
Kong et al. TREM1 Contributing to Glioblastoma Develop
Identification of Immune-Related Genes
The genes in the black module were sorted according to their
contribution to the clinical traits of the module, and the top 153
genes were selected. The intersection of these genes with GO
annotation for immune-related genes (total 148 genes) yielded a
list of 47 genes that are functionally involved in immunoreactions
and closely related to histopathological grade, TCGA subtype,
WHO grade, PFS, and OS (Figure 3A). To validate this list of
47 genes, we generated a heatmap using expression profiles and
clinical data from the TCGA database (Figure 3B). These genes
generally exhibited higher expression levels in IDH wild-type and
mesenchymal molecular subtype GBMs and lower expression
levels in low-grade gliomas, astrocytomas, IDH mutated GBMs,
and neural and pro-neural molecular subtype GBMs (Figure 3B
and Supplementary Figures 3A–C).
Identification of TREM1 as a Candidate
Biomarker for Poor Prognosis
We further characterized these 47 genes based on mRNA
expression, survival prognosis, and protein expression using
the TCGA GBM data. Immunohistochemistry images of
antibody staining in the human protein atlas database
were used to verify the protein expression of these genes
(https://www.proteinatlas.org/humanproteome/pathology)
(22). A group of candidate genes was chosen based on the
following three characteristics: 1. mRNA expression levels
were higher in GBMs than in non-tumor tissues; 2. high
expression of these genes was related to worse prognosis; 3.
positive IHC staining increased with increasing pathological
grade of glioma (Supplementary Figures 4A–E). Genes
with these characteristics included TREM1 (Figures 4A–C),
GBP2 (Figures 4D–F), IFITM2 (Figures 4G–I), CIITA
(Figures 4J–L), and TYROBP (Figures 4M–O). Due to
the fact that TREM1 appeared prominently in the black
module and little is known concerning a potential role in
GBM, we mainly focused on TREM1 for further analysis in
this study.
TREM1 Is Associated With Poor Prognosis
in All Databases
To validate TREM1 as a gene associated with prognosis,
we examined molecular features of the gene in samples in
the Rembrandt, TCGA, and CGGA databases. In all three
databases, the mRNA expression of TREM1 gradually increased
with increasing WHO grade (Figures 5A,B). Furthermore,
GBM TREM1high signified a worse prognosis than GBM
TREM1low (P = 0.0475; Figure 5C) using the Rembrandt
database. Non-G-CIMP-positive and mesenchymal molecular
GBM subtype tumors expressed higher levels of TREM1.
Many studies have demonstrated that non-G-CIMP-positive
and mesenchymal molecular subtypes correlate with worse
prognosis (Figures 5D,E). This result therefore indicated
that expression levels of TREM1, the G-CIMP state, and
GBM molecular subtypes may be linked. The analysis of
CGGA data also verified that the expression of TREM1 was
related to gender, age, WHO grade, molecular subtype, and









Age ≥45 67 58 15.38 <0.0001
<45 54 120
Gender Male 83 97 6.510 0.0107
Female 38 83
WHO II 18 98 52.61 <0.0001
Grade III 24 33
IV 76 48
TCGA- Classical 8 15 62.33 <0.0001
subtype Mesenchymal 86 25
Proneural 19 67
IDH1 WT 95 28 17.13 <0.0001
Mutation 3 10
PFS ≥643 34 114 33.27 <0.0001
<643 82 65
P-values were determined by chi-square and Fisher’s exact tests.
progression-free survival time (PFS) (Table 1). Nomograms
were constructed to predict the OS of an individual patient
based on a Cox proportional hazards regression model
(Supplementary Table 1).
We furthermore examined TREM1 protein expression
in images of immunostained GBM samples stored in the
Ivy Glioblastoma Atlas Project, which is a foundational
resource for exploring the anatomic and genetic basis
of GBM at the cellular and molecular levels (23). The
areas of GBM samples examined (based on H&E staining)
were the leading edge, infiltrating tumor, cellular tumor,
microvascular proliferation, and pseudopalisading cells around
necrosis. Higher expression of TREM1 appeared in areas of
pseudopalisading cells around necrosis than in other regions,
suggesting that TREM1 may be closely linked with hypoxia
(Figure 5F).
Analysis of reverse-phase protein array data (RPPA; a high-
throughput antibody-based technique) from the TCGA GBM
dataset yielded proteins significantly associated with TREM1,
including IFGBP2, TGM2 VEGFR2, and NDRG1, many of
which have also been linked to hypoxia (Figures 5B,G–I).
IGFBP2 has been reported to exert an oncogenic effect
by enhancing invasiveness, angiogenesis, and VM formation
and as part of a negative feedback loop with HIF1α in
glioma (24–26). It has also been correlated with classic
immunosuppressive biomarkers in glioma, such as CHI3L1,
TNFRSF1A, LGALS1, TIMP1, VEGFA, ANXA1, and LGALS3
(27). TGM2 has been reported to be highly expressed in glioma
tissues and therefore a possible diagnostic marker for glioma.
TGM2 has been shown to be related to hypoxia and HIF1α
in malignant pleural mesothelioma and gastric cancer (28).
NDRG1, a member of the N-myc downregulated gene family,
is involved in stress and hormone responses, cell growth, and
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FIGURE 3 | Identification of immune-related genes. (A) Venn diagram displaying the intersection between the top 153 genes in the black module and the top 148
immune-related genes. The 47 genes at the intersection of these two groups are listed in the table below. (B) Cluster heatmap generated from expression profiles and
clinical information of these 47 genes from the CGGA glioma database. IDH mutation, 0, wild type; 1, mutation; NA, unknown; A, astroglioma; AA, anaplastic
astrocytoma; AO, anaplastic oligodendroglioma; AOA, anaplastic oligodendroastrocytoma; GBM, glioblastoma multiforme; O, oligodendroglioma; NA, unknown; rA,
recurrent astroglioma; rAA, recurrent anaplastic astrocytoma; rAO, recurrent anaplastic oligodendroglioma; rAOA, recurrent anaplastic oligodendroastrocytoma;
rGBM, recurrent glioblastoma multiforme; sAA, secondary anaplastic astrocytoma; sAO, secondary anaplastic oligodendroglioma; sAOA, secondary anaplastic
oligodendroastrocytoma; sGBM, secondary glioblastoma multiforme.
differentiation, and is regarded as a mesenchymal marker in
GBM (29).
As one of the receptors for VEGF, VEGFR2 is a well-
recognized marker for hypoxia/angiogenesis. Actually, many
clinical trials using monoclonal antibodies (mAB) against
the protein have been carried out in an effort to block
tumor growth. However, clinical studies using bevacizumab,
a humanized mAb that blocks VEGFA signaling, did not
improve overall survival in patients with GBM (30). GBM often
develops resistance to bevacizumab owing to the upregulation of
alternative proangiogenic pathways and the induction of tumor
cell invasion (31). Moreover, differences in angiogenic responses
could originate from inter-individual GBM heterogeneity (32,
33). Although clinical results for inhibitors of VEGFR2 are
inconsistent, other strategies for blocking angiogenesis might still
hold promise for the treatment of GBM.
TREM1 and Glioma-Associated
Macrophages
We next performed Gene Set Enrichment Analysis (GSEA) to
obtain functional profiles for molecular signatures involving
TREM1 (34). The top functional profiles were associated with
angiogenesis, epithelial-mesenchymal transition, hypoxia,
IL6-JAK-STAT3 signaling, TNFα signaling via NF-κb,
inflammatory response, IL2-STAT5 signaling, and allograft
rejection (Figures 5C,J). These results indicated that TREM1
may be induced by hypoxia and participate in angiogenesis,
tumor cell migration, and other functions. This prediction has
been partially confirmed in a previous work demonstrating that
TREM1 was expressed on mature dendritic cells infiltrating
the inflamed hypoxic joints of children affected with juvenile
idiopathic arthritis. The engagement of TREM-1 elicited
DAP12-linked signaling, resulting in ERK-1, Akt, and
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FIGURE 4 | The mRNA expression, survival analysis, and protein expression of TREM1, GBP2, IFITM2, CIITA, and TYROBP using the TCGA data. The three columns
consist of images for mRNA levels of genes in non-neoplastic relative to GBM tissue samples, Kaplan-Meier survival curves for patients with genehigh vs. genelow
tumor samples, and IHC for each gene in non-neoplastic, LGG, and GBM tissue samples from the TCGA database. (A) TREM1 mRNA levels in non-neoplastic relative
to GBM tissue samples. (B) Kaplan–Meier survival curves for GBM patients with TREM1high and TREM1low tumors. (C) IHC of TREM1 in non-neoplastic tissues, LGG
and GBM. (D–F) GBP2; (G–I) IFITM2; (J–L) CIITA; (M–O) TYROBP. **P < 0.01; ***P < 0.001 compared to non-tumor tissue (scale bar: 100µm).
IκBα phosphorylation, and pro-inflammatory cytokine and
chemokine secretion (35).
Given the vital functions of immune co-stimulatory factors
and checkpoint molecules in the regulation of immune processes,
we performed correlation analysis to assess the relationship
between TREM1 and several well-known genes in GBM samples.
TREM1was correlated withCD40, PDCD1, TNFRSF4, TNFRSF9,
CD70, and CD86 (Figure 5K). These results corroborated a
previous study demonstrating that TREM1 was mainly expressed
in tumor-associated macrophages and induced by hypoxia,
thus participating in angiogenic and inflammatory responses.
Importantly, TREM1 expression was not detectable in GBM
cell lines under normoxia or hypoxia, indicating that TREM1
expression originated from cell types other than tumor cells
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FIGURE 5 | TREM1 is closely related to hypoxia and angiogenesis. TREM1 mRNA expression profiles based on pathological grade from (A) TCGA-Glioma and (B).
Rembrandt-Glioma datasets. (C) Kaplan–Meier survival curves for GBM patients with TREM1high and TREM1low tumors using the Rembrandt database. (D) TREM1
mRNA expression levels in different GBM molecular subtypes. (E) TREM1 mRNA expression levels in non-GIMP and GIMP positive samples from the TCGA. (F)
TREM1 mRNA expression levels in different pathologic areas/tumor microsections. Corresponding data were obtained from the Ivy Glioblastoma Atlas Project. Scatter
plots displaying the correlation between TREM1 mRNA expression and protein levels of (G) IGFBP2, (H) TGM2, and (I) VEGFR2. (J) The results of representative
GSEA analysis. (K) Chord diagram constructed from data on the correlation between TREM1 and immune co-stimulatory factor and checkpoint molecules. (L)
Heatmap generated with TREM1 mRNA expression levels in multiple immune cells using the TCGA-GBM dataset. Significant difference between the two groups: *P <
0.05; **P < 0.01;***P < 0.001.
(Supplementary Figures 5D,E) (36). We subsequently used
TIMER, a web server for comprehensive analysis of tumor-
infiltrating immune cells (https://cistrome.shinyapps.io/timer/)
and found that the mRNA expression levels of TREM1 were
inversely correlated with tumor purity in GBM (37). Specifically,
the mRNA expression levels of TREM1 were negatively
correlated with CD8-positive T-cell infiltration but positively
correlated with neutrophil and dendritic cell infiltration levels
(Figure 5F).
We also used Cibersort (https://cibersort.stanford.edu/) to
further explore the relationship between TREM1 and immune
cell infiltration. Cibersort converts gene expression profile data
into relative quantification of immune cells (38). We divided the
TCGAGBM data into high- and low-expression groups based on
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FIGURE 6 | Inhibition of TREM1 suppresses migration and vasculary mimicry formation of GBM cells in vitro. (A) RT-qPCR results for TREM1, CD206, and CD163 in
macrophages derived from the THP1 cell line under normoxia and hypoxia. (B) Western blot analysis of TREM1 protein levels under normoxia and hypoxia. (C)
Graphical representation of qRT-PCR after siRNA knockdown of TREM1. ACTB was used as an internal reference. (D) Western blot to validate the efficiency of
si-TREM1 knockdown in macrophages derived from the THP1 cell line. ACTB was used as a protein loading control. (E) Representative images of Transwell migration
for U87MG and LN229 under normoxia, hypoxia plus control, and hypoxia plus si-TREM1 (scale bar: 200µm). Statistical results of the invasive ratio with
corresponding treatment for 24 h in the Transwell assay. (F) Representative images of VM formation assay for U87MG in normoxia, hypoxia plus control, and hypoxia
plus si-TREM1. (G) RT-qPCR to detect mRNA expression of TGF-α, CSF1, CSF2, and VEGFA after knockdown of TREM1 under hypoxia. (H) Statistical results of the
invasive ratio for U87MG and LN229 in both control and pexidartinib (10µM) treatment under hypoxia. (I) Representative images of VM formation assay for U87MG in
both control and pexidartinib (10µM) groups under hypoxic conditions. Significant difference between the two groups: *P < 0.05; **P < 0.01; ***P < 0.001.
the median expression level of TREM1, quantified immune cell
populations, and plotted these results in heatmaps (Figure 5K).
We found that the percentage of M2 macrophages increased
significantly in GBM samples with high expression of TREM1.
Thus, we proposed that high expression of TREM1 plays a role in
promoting the development and progression of gliomas, similar
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to the mechanism of M2 macrophages in promoting the disease.
We therefore performed a series of experiments in vivo and in
vitro to test this hypothesis.
TREM1 Promotes GBM Cell Migration and
VM Formation
Hypoxic necrosis is a major feature in the diagnosis of GBM and
is closely related to stem cell maintenance, angiogenesis, energy
metabolism, and growth characteristics of tumor cells. Based
on the literature and our previous analysis, we hypothesized
that TREM1 may be induced by hypoxia. We also used
immunofluorescence to confirm that TREM1 was mainly
found to be expressed in macrophages (Figure 6A). TREM1
expression levels were increased in macrophages cultured under
hypoxic conditions relative to those cultured under normoxic
conditions. Markers of macrophage polarization, CD206 and
CD163 (markers of M2 polarization), were also elevated under
hypoxic conditions (Figures 6A,B).
Supernatants from hypoxic M2 macrophages have been
shown to promote the proliferation of pulmonary artery smooth
muscle cells (39). Inhibition of GTP cyclohydrolase (GCH1) was
discovered to shift the phenotype of TAMs from proangiogenic
M2 toward M1, accompanied by a shift in plasma chemokines
(40). Host-produced histidine-rich glycoproteins have also been
found to inhibit tumor growth and metastasis while improving
the effects of chemotherapy by skewing TAM polarization
away from M2 to a tumor-inhibiting M1-like phenotype
(41). TREM1 has been shown to act as an inflammatory
amplifier, specifically releasing pro-inflammatory chemokines
and cytokines or altering the expression of activated cell
membrane surfaces upon receipt of external stimuli. Therefore,
we suspect that increased TREM1 may play a role in promoting
tumor migration and angiogenesis through the release of certain
inflammatory factors. We therefore knocked down TREM1
with siRNAs in THP1 cells induced to become macrophages
and examined their role in promoting biological properties
of GBM cells such as migration. Western blot and qRCR
analysis were used to verify the knockdown efficiency of TREM1
(Figures 6C,D). After induction of siRNA-treated THP1 cells
into macrophages, they were cultured for 24 h under normoxia
and hypoxia, and supernatants were collected and mixed 1:1
with culture media containing 10% FBS for incubation with
GBM cells.
The results of Transwell and VM formation assays
demonstrated that hypoxia-induced macrophages promoted
U87 and LN229 tumor cell migration and vascular mimicry but
that this effect was significantly reduced after knockdown of
TREM1 (Figures 6B,E,F). To explore the molecular mechanism,
we compared the changes in expression levels of critical
cytokine mRNAs in macrophages under normoxic and hypoxic
conditions as well as between control and TREM1 knockdown
groups. Analysis of the intersection of significantly altered
genes in these two groups yielded CSF1 as a common factor
potentially involved in TREM1 (Figures 6C,G). To confirm
that CSF1 plays a role in promoting GBM cell migration
and vascular mimicry, induced macrophages were exposed to
pexidartinib (10µM), an inhibitor of the CSF1 receptor (CSF1R).
Supernatants from pexidartinib-treated macrophages relative to
controls significantly inhibited cell migration and pathological
angiogenesis under hypoxic conditions (Figures 6D,H,I). These
results indicated that hypoxia can induce upregulation of the
expression of TREM1 in macrophages, thereby promoting GBM
progression through the release of CSF-1, which triggers invasion
and vascular mimicry in GBM cells.
TREM1 Contributes to GBM Progression
in vivo
To investigate the effect of TREM1 on tumor growth in vivo, we
treated mice bearing orthotopic GBM xenograft with peptides
as a control and with LP17, which blocks TREM1. The results
from bioluminescence imaging demonstrated that tumor growth
was inhibited in animals treated with LP17 relative to controls
(∼ 16.3 × 107 vs. ∼ 8.2 × 107 photons/s, control vs. LP17-
treated; Figures 7A,B). The OS of tumor-bearing animals was
enhanced under treatment with LP17 compared to controls
(median survival, > 28 days vs. 20.5 days, LP17 and control
peptide, respectively, P < 0.05) (Figure 7C). Immunostaining
for CD11b positive cells in the LP17-treated group showed a
dramatic decrease compared to the control group (Figure 7D).
Sections stained with PAS showed that in the LP17 treatment
group, vascular mimicry was decreased compared to controls.
In summary, these data demonstrate that inhibition of TREM1
blocked the progression of GBM in vivo and may be used as a
therapeutic target.
DISCUSSION
The current standard of care for GBM includes surgery,
radiotherapy, and chemotherapy (temozolomide, TMZ). New
complications arise with each arm of this multi-modal treatment,
and tumors recur not long after the primary diagnosis. The
most promising approach in recent years for other tumor types
has been immunotherapy. Our present work also supports the
possibility of interfering with alternative immune cell types
typically infiltrating GBM. However, immunotherapy has not
proven satisfactory for the clinical treatment of GBM. For
example, although immune checkpoint inhibitors, such as anti-
programmed cell death (PD)1 antibody, have achieved better
prognosis in GBM animal models, a recent clinical trial indicated
that PD-1 inhibitors have an objective response rate of only 8%
in patients with recurrent GBM (7). In another approach, CAR-
T therapy has achieved tremendous success in hematological
malignancies. However, CAR-T therapy targeting EGFRvIII, a
tumor-specific antigen, has not achieved the desired clinical
results in GBM treatment (42).
Several possibilities might account for the reduced efficacy of
immunotherapy in GBM treatment. First, the immunocompetent
mouse models used to study immunotherapy do not accurately
reflect the human GBM TME. The methylcholanthrene-induced
GL261 and SMA-560 models are the commonly used orthotopic
xenograft models in GBM immunotherapy (27). However, both
model types possess a high number of mutations and predict
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FIGURE 7 | Inhibition of TREM1 suppresses tumor growth in vivo. (A) Representative bioluminescence images of tumor-bearing mice from control and LP-17
treatment groups at week 3. (B) Fluorescence quantitation for xenografts in animals from both groups at week 3. (C) Kaplan-Meier survival curves for tumor bearing
animals in control and LP-17 treatment groups. A log-rank test was used to assess the statistical significance of the differences. (D) Images of IHC staining for CD11b
and PAS staining in tumors from each group as indicated (scale bars: 50µm). (E) A hypothetical schematic diagram depicts how TREM1 promotes the development
of GBM. In hypoxic conditions, macrophages express increased levels of TREM1 and release more CSF1, which promotes pathological angiogenesis and migration of
GBM cells. *P < 0.05 compared to control.
neoepitopes and enhanced immune cell infiltration. These
features are in contrast to primary GBM samples, which typically
exhibit a low tumor mutational load and an immunosuppressive
microenvironment (8). Second, immune cell infiltration is
significantly less than in other solid tumors, rendering GBM a
so-called “cold” tumor. However, immune checkpoint inhibitors
still exert anti-GBM effects even though they rely on the recovery
of reactive T cells to execute a killing effect (9). Third, although
CAR-T therapy generates a significant increase in the number
of killer T cells, the presence of the BBB may limit their
access to brain tumors, unlike for other solid tumors. Moreover,
even after entering the tumor microenvironment, killer T cells
may have reduced killing potential due to hypoxic conditions
generated because of IDH variants and the heterogeneity of EGFR
mutations (7). Fourth, in addition to PD-L1, PD-1, and CTLA-
4, TMEs of GBM may also contain other immunosuppressive
factors, such as the A2aR high-affinity adenosine receptor
(on lymphocytes and tumor-associated macrophages) or PD-
L2 (on macrophages lacking PD-L1 expression). It has been
reported that anti-PD-L1 and anti-TIGIT (a novel immune
checkpoint inhibitor) combination therapy improved overall
survival in GBM patients by increasing effector T cell function
and downregulating the number of suppressive Tregs and tumor-
infiltrating dendritic cells (43).
In addition, both immune checkpoint inhibitors and CAR-
T therapy rely on killer T cells, but the GBM TME exhibits
mass macrophage infiltration, which includes phenotypically
suppressive CD163+ M2 to undifferentiated M0 macrophages,
particularly in the mesenchymal molecular GBM subtype
(30). Our laboratory has reported that hypoxic glioma-derived
exosomes deliver microRNA-1246 to induce M2 macrophage
polarization, which promotes proliferation, migration, and
invasion in vitro and in vivo of glioma cells by targeting
telomere binding repeat 2 interacting protein (TERF2IP) through
the STAT3 and NF-κB pathways (44). It was also found that
M2 macrophages enhance phosphoglycerate kinase 1 (PGK1)
threonine 243 phosphorylation, which facilitates glycolysis,
proliferation, and tumorigenesis in GBM cells (10). In the
present study, we also found that the expression levels of
TREM1 may be accompanied by an increase in macrophage M2
polarization. This result contradicts previous indications that
TREM1 is an M1 marker of macrophages in liver biopsies. The
reason for this discrepancy may be due to pathological and
tissue differences.
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Several other studies support a role for TREM1 in the
development of cancer. TREM1 has been reported to exert pro-
inflammatory immune responses not only in acute pathogen-
induced reactions but also in chronic and non-infectious
inflammatory disorders, including various types of cancer.
TREM1-/- mice exhibited reduced tumor number and load in
an experimental model of inflammation-driven tumorigenesis
of colorectal tumor (45). TREM1 has also been reported to
cooperate with diminished DNA damage response in vivo to
promote expansion and leukemic progression in Fanca-/- pre-
leukemia stem cells (46). Our present study demonstrated that
increased expression of TREM1 in macrophages may promote
GBM progression through the release of CSF1. The CSF1
receptor (CSF1R) has been investigated as a possible therapeutic
target in the treatment of GBM. Inhibition of CSF1R has been
shown to alter the expression of activated M2 markers and to
reduce intracranial growth of patient-derived glioma xenografts
(47). CSF1R ligand expression was also found to be elevated
in GBM xenografts treated with ionizing radiation (48). Both
studies indicate that inhibition of CSF1R might be a promising
strategy to improve the treatment and prognosis of GBM.
Besides TREM1, other genes may also have potential
therapeutic roles in GBM treatment. For instance, GBP2 was
found to inhibit mitochondrial fission and cell metastasis in
breast cancer cells both in vitro and in vivo (49). Further, IFITM2
was significantly up-regulated and induced after activation of
beta-catenin signaling in colorectal cancers (50), and it was
also reported to promote gastric cancer growth and metastasis
through the insulin-like growth factor (IGF1)/IGF1 receptor
(IGF1R)/STAT3 signaling pathway (51). CIITA, a member of
the interferon response factor (IRF) pathway, was found by
integrative genomic analysis to be a key oncogenic gene in
primary mediastinal large B-cell lymphoma (52). TYROBP, a
downstream effector of TREM1, induced the transformation of
microglial cells and regulated inflammatory response (53). Thus,
all of these genes will be highly interesting for studies of GBM.
In summary, we analyzed the GBM data in the CGGA
database using WGCNA to obtain immune-related genes
that may promote the progression of GBM. TREM1 emerged
as a gene of interest due to higher expression in GBMs
relative to non-neoplastic tissue and association with a
worse prognosis. The expression of TREM1 increased in
macrophages under hypoxia, and supernatants from these
cells promoted pathological angiogenesis and migration
of GBM cells in vitro. A possible factor mediating this
response is CSF1 (Figure 7E). These results underscore
the importance of the TME in GBM development. Thus,
targeting the tumor microenvironment, or specifically
TAMs, allow a vulnerability in the development of GBM
to be exploited and should be considered as a viable
therapeutic strategy.
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Supplementary Figure 1 | (A) Network topology for different soft-thresholding
powers. Numbers in the plots indicate the corresponding soft thresholding
powers. The approximate scale-free topology can be attained at a
soft-thresholding power of 5. (B) Assessing the scale-free topology when the
soft-thresholding power was set to 5 (scale-free R2 = 0.84, slope = −1.35). (C)
Eigengene adjacency heatmap. Different colors indicate the degree of correlation
between modules.
Supplementary Figure 2 | (A) Heatmap for gene expression in black modules.
The average expression of the eigenvectors of the black module is highly
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correlated with the expression of genes within the black module.
(B) Protein–protein interaction network consisting of all genes in the black module.
Supplementary Figure 3 | The expression of intersection genes in different
groups based on the CGGA database. (A) Expression of IDH wild-type and
mutant. (B) Expression of LGG and GBM. (C) Expression of the
non-mesenchymal subgroup and mesenchymal subgroup.
Supplementary Figure 4 | Quantitative graph of IHC staining in normal tissue
and glioma samples. (A) TREM1; (B) GBP2; (C) IFITM2; (D) CIITA; and (E)
TYROBP. Significant difference between the two groups: ∗P < 0.05; ∗∗P < 0.01;
∗∗∗P < 0.001.
Supplementary Figure 5 | (A) TREM1 mRNA expression levels in both LGG and
GBM samples from the CGGA database. (B) Scatter plot displaying the
correlation between TREM1 mRNA expression levels and NDRG1pT346 protein
levels. (C) GSEA highlighting a positive association of increased TREM1
expression levels with inflammatory response, IL2-STAT5 signaling, and allograft
rejection. (D) Immunofluorescence staining of GBM tissue sections. Red
represents TREM1, blue represents DAPI (scale bar: 100µm). (E) Western blot
analysis of TREM1 protein levels in three GBM cell lines under normoxia and
hypoxia. (F) The correlation between TREM1 mRNA expression and immune
infiltration levels in GBM. These images were generated using TIMER.
Supplementary Figure 6 | (A) Immunofluorescence staining of GBM tissue
sections. Red represents TREM1, green represents CD11b and CD68,
respectively, and blue represents DAPI (scale bar: 100µm). (B)
Immunofluorescence staining of VM for U87MG under hypoxia condition plus
control or si-TREM1. Green represents VEGFR2, and blue represents DAPI (scale
bar: 100µm). (C) mRNA expressions of TGF-α, IL1β, IL6, IL10, CSF1, CSF2,
CXCL, and VEGFA were detected under normoxia and hypoxia. (D)
Representative images of Transwell migration for U87MG and LN229 in both
control and pexidartinib treatment under hypoxia (scale bar: 200µm). Significant
difference between the two groups: ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.
Supplementary Table 1 | Nomogram for predicting the proportion of glioma
patients with OS based on the TCGA database.
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